1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib
Helena A. Yu(Memorial Sloan Kettering Cancer Center), Xiuning Le(The University of Texas MD Anderson Cancer Center), Sarah B. Goldberg(Yale University), Jonathan W. Goldman(University of California, Los Angeles), Michael Pluta(AstraZeneca (United Kingdom)), Silvija Kraljevic(AstraZeneca (United Kingdom)), Christina S. Baik(Seattle Cancer Care Alliance), Emiliano Cocco(AstraZeneca (United States)), Adrianus J. de Langen(The Netherlands Cancer Institute), Zofia Piotrowska(Global Cancer Institute), Isamu Okamoto(Kyushu University Hospital), Jonathan W. Riess(University of California Davis Medical Center), N. Reguart Aransay(Hospital Clínic de Barcelona), B.C. Cho(Yonsei University), Helen Ambrose(AstraZeneca (United Kingdom)), S. Powar(AstraZeneca (United Kingdom))
Cited by 47
Related Papers
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
|Clinical Cancer Research|2016|1.2k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
|New England Journal of Medicine|2020|879